CareDx Focuses on Innovation in Transplant at ASN Kidney Week
Two AlloSure abstracts will be featured at ASN, and CareDx will showcase innovations in transplantation at a virtual event on November 5
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced key data and presentations at the American Society of Nephrology (ASN) Kidney Week 2021, which will be held virtually from November 4-7, 2021.
At ASN Kidney Week, CareDx is featured in two clinical abstracts that continue to support the utility of AlloSure® as an important surveillance tool for transplant patient management.
- Diagnostic Performance of Donor-Derived Cell-Free DNA Assay (AlloSure®) in Kidney Transplant Recipients with Graft Dysfunction: A Single-Center Study, November 4, 10:00 AM – 12:00 PM ET
- Elevation in Donor-Derived Cell-Free DNA Triggered by COVID-19 Vaccination
Additionally, in conjunction with Kidney Week 2021, CareDx is hosting a virtual Transplant Innovation Day on Friday, November 5 from 12:00-1:00 PM ET. Dr. Robert Montgomery from New York University Langone Transplant Institute will provide key insights into the first xenotransplant of a kidney grown in a genetically altered pig into a human. Dr. Enver Akalin from Montefiore Medical Center will present the AlloMap Kidney validation data. David-Alexandre (DA) Gros, CEO of Eledon Pharmaceuticals, will discuss the partnership with CareDx to further transplant therapeutics clinical trials. Dr. Titte Srinivas, Vice President of Digital Development and Clinical Integration at CareDx, will review independent validation data with AlloSure in over 1000 patients. Registration for the Transplant Innovation Day is available here.
“I look forward to presenting our AlloSure study at ASN as it furthers our clinical understanding of dd-cfDNA levels in kidney transplantation and how those relate to long-term outcomes for patients,” said Kalathil K. Sureshkumar, MD, Allegheny Health Network. “I believe this analysis will have real-world implications as it supports AlloSure clinical utility for patients.”
“CareDx is a leader in driving innovation in transplantation, and I am glad we can highlight this focus during Kidney Week with new data and an exceptional virtual event to support investment into transplant science,” said Reg Seeto, CEO of CareDx.
CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements related to CareDx, Inc., including statements regarding CareDx’s presentations at the American Society of Nephrology (“ASN”) Kidney Week 2021 (the “ASN Presentations”), the Transplant Innovation Day to be hosted by CareDx on November 5, 2021 (the “TID Event”), and the potential benefits and results that may be achieved through the ASN Presentations and the TID Event. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that the CareDx does not realize the expected benefits of the ASN Presentations and the TID Event; risks that CareDx fails to present the two clinical abstracts on AlloSure study in ASN Kidney Week 2021; risks that speakers at the TID Event fail to provide insights and data or to discuss partnership as planned; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed by CareDx with the SEC on February 24, 2021 and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
Chief Marketing Officer